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Histone deacetylase inhibitors (HDACIs) are novel anticancer agents with potent cytotoxicity against a wide range of malignancies.
We have previously demonstrated that either Calphostin C (CC) (a protein kinase C (PKC) inhibitor) or Parthenolide (an NF-kB
inhibitor) abrogates HDACI-induced transcriptional activation of NF-kB and p21, which is associated with profound potentiation of
HDACI-mediated induction of apoptosis. Valproic acid (VA), a commonly used antiepileptic agent, has recently been shown to be an
HDACI. This study was aimed to evaluate the anticancer property of VA in thoracic cancer cells and the development of clinically
relevant strategies to enhance VA-mediated induction of apoptosis using kinase inhibitors Staurosporine (STP) or its analogue UCN-
01. Treating cultured thoracic cancer cells with VA (0.62–10.0mM) resulted in significant cell line- and dose-dependent growth
inhibition (IC50 values: 4.1–6.0mM) and cell cycle arrest at G1/S checkpoint with profound accumulation of cells at G0/G1 phase but
little induction of apoptosis. Valproic acid, being an HDACI, caused significant dose-dependent accumulation of hyperacetylated
histones, following 24h of treatment. Valproic acid-mediated 5–20-fold upregulation of transcriptional activity of NF-kB was
substantially (50–90%) suppressed by cotreatment with CC, STP or UCN-01. Whereas minimal death (o20%) was observed in
cells treated with either VA (1.0 or 5.0mM) alone or kinase inhibitors alone, 60–90% of cells underwent apoptosis following
exposure to combinations of VAþkinase inhibitors. Kinase inhibitor-mediated suppression of NF-kB transcriptional activity played an
important role in sensitising cancer cells to VA as direct inhibition of NF-kB by Parthenolide drastically synergised with VA to induce
apoptosis (VAþParthenolide: 60–90% compared to o20% following single-drug treatments). In conclusion, VA, a well-known
antiepileptic drug, has mild growth-inhibitory activity on cultured cancer cells. The weak VA-mediated induction of apoptosis of
thoracic cancer cells can be profoundly enhanced either by Parthenolide, a pharmacologic inhibitor of NF-kB, or by UCN-01 a kinase
inhibitor that has already undergone phase I clinical development. Combinations of VA with either a PKC inhibitor or an NF-kB
inhibitor are promising novel molecularly targeted therapeutics for thoracic cancers.
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Chromatin remodelling via histone acetylation by histone acetyl-
transferases and histone deacetylases (HDACs) is considered as a
key element in the dynamic regulation of many genes that play
crucial roles in cell growth and differentiation (Kramer et al, 2003;
Rosato and Grant, 2004). Chromatin structure, in its compact
hypoacetylated state, may affect gene expression by blocking the
access of transcription factors to their cognate DNA sequences to
initiate gene transcription. On the other hand, chromatins with
hyperacetylated core histones, due to acetylation-mediated neu-
tralisation of positive charges on lysine residues and disruption of
nucleosome structures, assume a relaxed conformation with
unfolding of associated DNA that facilitates transcriptional activity
(Grunstein, 1997; Richon et al, 1998; Struhl, 1998; Wolffe and
Kurumizaka, 1998; Sambucetti et al, 1999). Histone deacetylases
have been shown to be involved in oncogenic transformation by
mediating the function of transcription factors in certain forms of
haematologic malignancies and possibly in the pathogenesis of
solid tumours (Rosato and Grant, 2004). Therefore, identification
and clinical development of pharmacologic inhibitors of HDACs
for anticancer therapy have attracted a great deal of interest.
Histone deacetylase inhibitors (HDACIs) are structurally diverse
chemical compounds that share common biological properties of
inducing core histone hyperacetylation leading to gene expression
and of mediating potent antitumour effects. Some of HDACIs are
either naturally occurring compound like sodium butyrate, a fatty
acid metabolite found in high concentration in the lumen of large Revised 22 March 2006; accepted 30 March 2006
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sintestine, or pharmacologic compound such as valproic acid (VA),
a commonly prescribed antiepileptic drug whose pharmaco-
kinetics and toxicity profiles are well documented (Brodie and
Dichter, 1996; Blaheta and Cinatl, 2002), whereas others are
complex chemicals isolated from culture broths of microorganisms
(such as Depsipeptide, Apicidin or Trichostin A (TSA)) or
synthetic derivatives (for instance MS-275, CI-994). Histone
deacetylase inhibitors are subdivided into four fundamental
groups: short-chain fatty acids (sodium butyrate, phenylbutyrate,
valproic acid), synthetic benzanide derivatives (MS-275, CI-994),
cyclic tetrapeptides (Depsipeptide, Trapoxin, Apicidin) and
hydroxamic acids (TSA, suberoylanilide hydroxamic acid (SAHA),
LAQ8240) (Rosato and Grant, 2004). Histone deacetylase inhibi-
tors induce differentiation, cell cycle arrest and/or apoptosis of
cancer cells in culture and in vivo animal models (Jaboin et al,
2002; Rosato and Grant, 2004; Schrump and Nguyen, 2005).
Multiple HDACIs (sodium butyrate, SAHA, Depsipeptide, MS275)
have been shown to have anticancer properties in phase I and II
clinical trials (Schrump et al, 2002; Kelly et al, 2003; Piekarz and
Bates, 2004; Rosato and Grant, 2004).
The antitumour activity of HDACIs has been attributed to both
their ability to inhibit deacetylases (leading to accumulation of
hyperacetylated histones and alteration of gene transcription) and
their ability to downregulate phenotypic expression of onco-
proteins as well as activation of the intrinsic apoptosis-inducing
cascade (Ruefli et al, 2001; Yu et al, 2002; Marks and Jiang, 2005).
Histone deacetylase inhibitor-mediated cell cycle arrests or
induction of apoptosis are dependent on treatment conditions
such as drug concentrations and duration of drug exposure, as well
as the intrinsic sensitivity of malignant cells to this class of
anticancer agents (Yu et al, 2002; Maxhimer et al, 2005). Activation
of NF-kB transcriptional activity and upregulation of p21 gene
expression are frequently observed following HDACI treatments in
cancer cells (Burgess et al, 2001; Dai et al, 2003; Mayo et al, 2003).
Histone deacetylase inhibitor-mediated activation of NF-kB acti-
vity and/or upregulation of p21 gene expression have actually been
shown to impede drug-induced apoptosis (Burgess et al, 2001; Mayo
et al, 2003; Nguyen et al, 2003, 2004; Rosato et al, 2004; Rundall
et al,2 0 0 4 ;M a x h i m e ret al, 2005). In fact, inhibition of HDACI-
induced NF-kB activation by pharmacologic inhibitors of IkB kinase
inhibitor (IKK) or by overexpression of kinase-resistant IkB
resulted in substantial induction of apoptosis of HDACI-treated
cells (Rundall et al, 2004; Maxhimer et al, 2005). Similarly, depletion
of p21 by antisense oligonucleotides sensitises cultured cancer cells
to HDACIs (Burgess et al, 2001). The molecular pathways that
regulate HDACI-mediated NF-kB activation seem to involve PI3K/
Akt (Mayo et al, 2003) and/or protein kinase C (PKC) signallings
(Kim et al, 2003; Maxhimer et al, 2005). Mayo et al (2003) have
demonstrated that the ability of HDACIs to increase NF-kB
transcriptional activity was not associated with events that
stimulated nuclear translocation, but rather related to modulation
of transactivation potential of the RelA/p65 subunit of NF-kBv i aa
PI3K/Akt-dependent mechanism. Maxhimer et al (2005) have
shown that the PKC inhibitor Calphostin C (CC) completely
abrogated TSA-mediated NF-kB activation in cultured thoracic
cancer cells and this was associated with profound induction of
apoptosis following treatment with CCþTSA drug combination.
Moreover, Grant and his co-workers (Rosato et al, 2002; Rahmani
et al, 2003a,b) as well as our group (Nguyen et al, 2003, 2004) have
published multiple reports that described the synergistic interac-
tions between HDACIs and different kinase inhibitors (for instance,
Flavopiridol or LY294002) to induce massive apoptosis in leukaemic
or thoracic cancer cells in vitro. These findings support further
preclinical and clinical development of targeted therapeutic stra-
tegies that combine inhibition of either NF-kBo rP I 3 Ko rP K C
signallings with HDACIs by using clinically relevant pharmacologies.
Staurosporine (STP) and its analogue UCN-01 were initially
developed as PKC inhibitors for cancer therapy (Seynaeve et al,
1994). More recent studies have identified these compounds as
kinase inhibitors with a broader range of molecular targets in vivo,
including chk1/2 and PDK1, a kinase that act directly upstream of
Akt and MAP/extracellular signal-regulated kinase (ERK) kinase
(MEK) (Sato et al, 2002). Exposure of cultured cancer cells to
UCN-01 (250–1000nM) resulted in complete abrogation of
phosphorylation at Ser473 and Thr308 residues of Akt, both of
which are essential for full activation of Akt kinase activity
(Amornphimoltham et al, 2004; Kondapaka et al, 2004). Clinical
trials of UCN-01 in patients with refractory neoplasms, as
monotherapy or in combination with cytotoxic chemotherapeutics,
have been reported (Sausville et al, 2001). Continuous 72-h
infusion of UCN-01 resulted in ‘free’ (after ultracentrifugation)
plasma drug concentrations of 200–600nM and tissue drug
concentration (via measurement of salivary UCN-01 concentra-
tions as surrogates) of 110nM (Sausville et al, 2001). In view of the
facts that STP and its clinically relevant analogue UCN-01 inhibit
multiple kinases known to influence the cytotoxic effect of HDACIs
in cancer cells, we hypothesised that STP or UCN-01 would
synergise with HDACIs to promote profound induction of
apoptosis. To this end, we sought to investigate the cytotoxicity
of the UCN-01þVA combination in cultured thoracic cancer cells
in vitro. These agents have been used in human for different
indications, the former as a phase I anticancer agent and the latter
as an established antiepileptic drug that was recently demonstrated
to have anticancer activity in vitro and in vivo animal model
(Gottlicher et al, 2001). This combination has the potential to be
developed into a clinically applicable novel targeted molecular
therapeutics.
MATERIALS AND METHODS
Cells and reagents
The oesophageal cancer (EsC) cells TE2, TE12; the non-small-cell
lung cancer (NSCLC) cells H322, H460 and the malignant pleural
mesothelioma (MPM) cells H513, H211 were maintained in RPMI-
1640 culture medium supplemented with fetal calf serum (10%
volvol
 1), streptomycin (100mgml
 1), penicillin (100Uml
 1) and
glutamine (2mM). Trichostatin A (Sigma, St Louis, MO, USA),
Calphostin C, STP, (Calbiochem, La Jolla, CA, USA) and the NF-kB
inhibitor Parthenolide (Alexis, San Diego, CA, USA) were
dissolved in dimethyl sulphoxide and stored at  201C. Valproic
acid (Alexis) was dissolved in distilled water to make 500mM stock
and stored in 41C. UCN-01 was provided by the Developmental
Therapeutic Programme of the National Cancer Institute, NIH,
Bethesda, MD, USA.
Determination of apoptosis
Cancer cells seeded at 3 10
5 cells per well in six-well plates were
treated either with VA alone (1.0. or 5.0mM) or in combination
with CC (1.0–2.0mM), UCN-01 (250–500nM), STP (200nM)o r
Parthenolide (20mM). The second drug was added into the VA-
treated cells 12h after the onset of VA treatment as 10  stock
solutions with VA remained in the cultured medium. Treated cells
were harvested at 48h after the onset of VA treatment, fixed in 1%
paraformaldehyde and 70% ethanol, and assayed for apoptosis by
using the terminal deoxynucleotidyltransferase-mediated dUTP
nick-end labelling (TUNEL)-based ApoBrdU assay (BD Pharmin-
gen, Torrance, CA, USA), as per the protocol provided by the
manufacturer.
NF-jB transcriptional activity
The transcriptional activity of NF-kB was evaluated by transient
transfection of NF-kB-luciferase reporter plasmid (Invitrogen,
Carlsbad, CA, USA) into cells before drug treatments. Luciferase
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sactivity of cell lysates is directly correlated with the transcriptional
activity of NF-kB. Cells were plated onto 24-well plates at a density
of 8 10
4 cells well
 1. For transcription experiments, cells were
transfected with 200ng of NF-kB-Luc plasmid per well with Fugene
(Promega, Madison, WI, USA). At 24h after transfection, cells
were treated with different experimental conditions as outlined in
the respective figure legends. The transcriptional activity of NF-kB
was quantified by measuring the luciferase activity from cell
lysates with Luciferase Assay System (Promega, Madison, WI,
USA) and the Lumat LB 9507 lucinometer (EG&G Berthold,
Gaithersburg, MD, USA). The NF-kB activity was normalised with
the total cellular protein in cell lysates determined by BCA protein
assay (Pierce Biotechnology, Rockford, IL, USA) and expressed as
fold of the NF-kB activity of untreated control cells.
Western blotting
Cultured NSCLC and EsC cells were treated with different
experimental conditions as described in the figure legends.
Whole-cell extracts were prepared in cell lysis buffer (Cell
Signaling Technologies, Beverly, MA, USA) supplemented with
1m M PMSF (Sigma, St Louis, MO, USA). In total, 50mg of cell
extracts were separated on a gradient 4–20% SDS–PAGE and
transferred onto nitrocellulose membranes. The membranes were
blocked in 5% Blotto before immunoblotting with antibodies
targeting apoptotic proteins Bax, Bak, Bcl2, BclXL (Cell Signaling
Technology, Beverly, MA, USA at 1:1000 dilution) and cIAP1
(R&D, Minneapolis, MN, USA, 1:2000 dilution). Nitrocellolose
membranes were also immunoblotted with antibodies targeting
phospho-Adducin (Upstate, Waltham, MA, USA, 1:1000 dilution
with 3% Blotto), Akt and phospho-Akt Ser473 (Cell Signaling,
1:500 dilution with 5% BSA), p42/p44 and phospho-p42/p44 (Cell
Signaling, 1:1000 dilution with 5% BSA) and acetylated-Histones 3
and 4 (Upstate, 1:1000 dilution with 3% Blotto). The primary
antibodies were detected by HRP-conjugated anti-mouse and anti-
rabbit secondary antibodies and detected with West Dura
chemiluminescence (Pierce Biotechnology, Rockford, IL, USA).
Data analysis
Supra-additive apoptosis is defined as the apoptosis induced by
the drug combinations that is, by statistical analysis, significantly
greater than the algebraic sum of apoptosis induced by individual
drug treatment. Data are expressed as means7standard error of
the means (s.e.m.) of at least three independent experiments that
yielded similar results. Statistical analysis was performed with the
GraphPad InStat software (GraphPad, San Diego, CA, USA).
Statistical analysis was performed using analysis of variance
(ANOVA) and pairwise comparison using Bonferroni test or by
two-tailed Student’s t-test, with Po0.05 indicating statistical
significance.
RESULTS
Staurosporine or UCN-01 suppresses TSA-mediated NF-jB
activation and enhances TSA-induced apoptosis
As we have previously demonstrated that pharmacologic inhibi-
tion of PKC activity by using CC resulted in abrogation of TSA-
mediated NF-kB activation and enhancement of apoptosis in cells
treated with the TSAþCC combination (Maxhimer et al, 2005), we
sought to determine if STP or UCN-01, via being PKC inhibitors as
indicated by their ability to markedly reduce the expression of
phosphorylated a/g adducin (p-adducin) (Figure 1A), could
duplicate the effect of CC in suppressing NF-kB activation and
enhancing the cytotoxic effect of TSA in cultured thoracic cancer
cells. Staurosporine (200nM) or UCN-01 (500nM) significantly
inhibited NF-kB transcriptional activation in H322 and TE12 cells
that were treated with TSA, quite similar to the effect of the PKC
inhibitor CC (Figure 1A). Whereas less than 20% of cultured
thoracic cancer cells exposed to either CC, STP or UCN-01 alone or
TSA alone were apoptotic, 55% to more than 90% of cells treated
with the respective drug combinations had undergone apoptosis
(Figure 1B). However, the supra-additive induction of apoptosis by
UCN-01 or STP in combination with TSA may also be attributable
to their function as negative modulators of Akt and MEK/ERK1/2
activation via inhibition of PDK1 (Sato et al, 2002), in addition to
being PKC inhibitors. To further investigate the effect of STP or
UCN-01 on MAPK ERK1/2 or Akt activation in cultured thoracic
cancer cells, dose–response and time-course studies were
performed on cells treated with STP (100–400nM) or UCN-01
(250–1000nM) and harvested at 1 or 24h after the onset of drug
exposure (Figure 2). UCN-01 treatment resulted in a significant
dose-dependent reduction of pAkt as early as 1h after drug
exposure. At 24h, higher phosphorylated Akt levels were observed
in UCN-01-treated cells than in untreated controls. Staurosporine,
on the other hand, mediated a dose-dependent activation of Akt
throughout the whole time-course experiment. Dose-dependent
suppression of ERK1/2 activation, however, was observed in both
STP- and UCN-01-treated cells at both time points. As expected,
PKC activity in cultured thoracic cancer cells, as indicated by
p-adducin levels, was completely abrogated by either STP or
UCN-01, with STP mediating a very rapid onset of PKC inhibition
and UCN-01 mediating a slower onset of PKC inhibition.
The growth-inhibitory effect of VA in cultured thoracic
cancer cells
Subsequent experiments were devoted to evaluating the antitu-
mour effect of VA in cultured thoracic cancer cells. Valproic acid
has been shown to have HDACI activity and to mediate
differentiation and/or apoptosis in different carcinoma cell lines
in vitro and in vivo (Gottlicher et al, 2001; Phiel et al, 2001; Kramer
et al, 2003; Gurvich et al, 2004). Valproic acid also exhibited
HDACI activity in cultured thoracic cancer cells. Treating
representative NSCLC cells H460, EsC cells TE12 and MPM cells
H513 with VA resulted in a dose-dependent accumulation of
hyperacetylated H3 and H4 histones (Figure 3A). Valproic acid
mediated a mild reduction of cell proliferation, the magnitude of
which was cell line-dependent with the VA IC50 values ranging
from 4.5 to 8.0mM (Figure 3A). The effect of VA on the
progression of cancer cells through the cell cycle was determined
by PI staining and flow cytometry. Treating cultured thoracic
cancer cells with VA (1.0 or 5.0mM) for 48h resulted in
accumulation of cells in G0/G1 phase and a concomitant reduction
of cell in S and G2/M phases, indicating that VA mediated cell cycle
arrest at the G1/S checkpoint (Figure 3B). Similar to previous
reports (Gottlicher et al, 2001; Kramer et al, 2003), VA was a weak
inducer of apoptosis in thoracic cancer cell lines as less than 25%
of cells were apoptotic following 48h of continuous exposure to
high concentration of VA at 5.0mM (Figure 3C). By itself, VA
exerted a very mild growth-inhibitory effect, yet we postulated that
the cytotoxic effect of VA, being an HDACI, could be enhanced by
the PKC inhibitor CC or the broader spectrum kinase inhibitor
STP or UCN-01. These kinase inhibitors negatively regulate PKC
and ERK1/2 activation, both of which have been shown to
potentiate the cytotoxic effect of HDACIs (Rahmani et al, 2003b;
Maxhimer et al, 2005).
Profound enhancement of apoptosis induction by
combining VA with kinase inhibitors
We first determined if VA, as an HDACI, would induce activation
of NF-kB transcriptional activity that could be suppressed by
kinase inhibitor CC, STP or UCN-01 as was previously demon-
strated with TSA. Treating NSCLC cells H460, EsC cells TE12 or the
Anticancer effect of valproic acid
W-S Yeow et al
1438
British Journal of Cancer (2006) 94(10), 1436–1445 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s45
40
35
30
25
20
15
10
5
0
# # + +
+
+ +
+ +
+
+
Control CC STP UCN-01 CC STP UCN-01 Control
N
F
-

B
 
t
r
a
n
s
c
r
i
p
t
i
o
n
a
l
 
a
c
t
i
v
i
t
y
(
f
o
l
d
 
o
f
 
u
n
t
r
e
a
t
e
d
 
c
o
n
t
r
o
l
)
TE12
H322j TE 12
TSA (2 M)
H322
Cell lines
Normal media
TSA 0.1 M
TSA 1.0 M
2.3% 2.0%
1.7% 58%
25% 99%
0 200 400 600 8001000
104
103
102
101
100
6.7%
0 200 400 600 8001000
104
103
102
101
100
64%
TSA (1 M)
2.5% 17%
11% 97%
17% 71%
0 200 400 600 8001000
104
103
102
101
100
13%
0 200 400 600 8001000
104
103
102
101
100
0 200 400 600 8001000
104
103
102
101
100
0 200 400 600 8001000
104
103
102
101
100
0 200 400 600 8001000
104
103
102
101
100
0 200 400 600 8001000
104
103
102
101
100
0 200 400 600 8001000
104
103
102
101
100
0 200 400 600 8001000
104
103
102
101
100
0 200 400 600 8001000
104
103
102
101
100
0 200 400 600 8001000
104
103
102
101
100
0 200 400 600 8001000
104
103
102
101
100
0 200 400 600 8001000
104
103
102
101
100
0 200 400 600 8001000
104
103
102
101
100
0 200 400 600 8001000
104
103
102
101
100
73%
N
o
r
m
a
l
 
m
e
d
i
a
C
a
l
p
h
o
s
t
i
n
 
C
 
(
1
 

M
)
S
t
a
u
r
o
s
p
o
r
i
n
 
(
2
0
0
 
n
M
)
U
C
N
-
0
1
 
(
5
0
0
 
n
M
)
A
B
Figure 1 (A) Suppression of TSA-mediated upregulation of NF-kB transcriptional activity by Calphostin C, Staurosporine and its analogue UCN-01 in
NSCLC cell H322 and EsC cell TE12. Cells were transiently transfected with NF-kB-Luc plasmid as described in Materials and Methods and then
subsequently treated with TSA (0.1 and 1.0mM) with or without concurrent Calphostin C (CC – 2mM), Staurosporine (STP – 200nM) or UCN-01 (500nM).
Staurosporine and UCN-01 exerted a potent PKC-inhibitory activity as evidenced by the complete depletion of p-adducin following 12h of exposure to the
respective drugs. Luciferase activity assayed 24h after drug treatments were normalised for proteins of cell lysates and expressed as fold of activity of
untreated control cells. Data are expressed as mean7s.e.m. of three independent experiments (#Po0.05–0.01 and þPo0.001 vs controls by ANOVA
and pair-wise comparison by Bonferroni test). (B) Profound induction of apoptosis in H322 and TE12 cells treated with TSAþCC, TSAþSTP and
TSAþUCN-01 combinations. Cells were exposed to TSA (1 or 2mM) for 12h, to CC (1mM) or STP (200nM) or UCN-01 (500nM) continuously for 36h or
TSA followed by other drugs. Cells were then harvested 48h after the onset of treatment to assay for apoptosis. Representative data of three independent
experiments that yielded similar results are shown here.
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sMPM cells H211 with VA (1.0 or 5.0mM) for 24h resulted in a cell
line- and dose-dependent 5–20-fold increase of NF-kB transcrip-
tional activity (Figure 4). Such robust upregulation of NF-kB
activity was significantly suppressed by CC (2mM), STP (200nM)o r
UCN-01 (500nM) when assayed 24h after exposure to the
respective drug combinations (Figure 4). Staurosporine was most
effective among the kinase inhibitors at inhibiting VA-mediated
NF-kB activation. UCN-01, on the other hand, in best experimental
conditions mediated 50% (two-fold) to 70% (three-fold) reduction
of VA-mediated NF-kB activation. Moreover, there was significant
reduction in the levels of the antiapoptotic proteins cIAP1, BclXL
and Bcl2 without discernible alterations in the levels of proapop-
totic proteins Bax, Bak in H460 or TE12 cells treated with the
VAþUCN-01 combinations (Figure 5). The lack of alteration of
Bax and Bak, taken together with reduction of the levels of
antiapoptotic proteins in cancer cells exposed to the VAþUCN-01
combination, would favour a more proapoptotic milieu within
treated cells. Moreover, the effect of UCN-01 on ERK1/2, Akt and
PKC activity in VA-treated cells was evaluated by Western blotting
for levels of pERK1/2, pAkt and p-adducin (Figure 6). Valproic
acid mediated a dose-dependent upregulation of PKC kinase
activity as indicated by increased p-adducin levels in H460 and
H513 cells, whereas there was no discernable alteration of the
already high basal p-adducin level in TE12 cells and these were
completely abrogated by UCN-01. Similarly, UCN-01 significantly
inhibited ERK1/2 activation in VA-treated H460 and TE12 cells but
not H513 cells. On the other hand, UCN-01 mediated a clear
1 h post-treatment H460 TE12
pAkt (Ser473)
Akt
pERK 1/2
ERK 1/2
pAdducin
pAdducin
24 h post-treatment
pAkt (Ser473)
pERK 1/2
c 100 200
STP
400 250 500 1000 c 100 200
STP
400 250 500 1000
Figure 2 Time-course (1 and 24h) and dose-dependent STP (50, 100,
200nM)- or UCN-01 (250, 500, 1000nM)-mediated modulation of the PKC
activity and of phosphorylated Akt, ERK1/2 levels in H460 and TE12 cells.
b-Actin of cell lysates was blotted to indicate equal loadings of proteins.
Profound depletion of pERK1/2, p-adducin and pAkt (in early time points)
following UCN-01 exposure. Staurosporine effect on these molecular
targets was similar to the effect of UCN-01, except that it stimulated
(instead of inhibited) Akt phosphorylation.
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Figure 3 (A) The HDAC-inhibitory activity of VA in H460, TE12 and
H513 cells. Cells were treated with VA (0.5, 1.0 and 5.0mM) for 12h and
hyperacetylated H3 and H4 histone proteins were determined by Western
blot analysis. Mild growth-inhibitory effect of VA on cultured thoracic
cancer cells. Cells, seeded in 96-well microtiter plates, were continuously
exposed to VA (0.62–10.0mM) for 96h. Cell viability was measured by
MTT (4,5-dimethylthiazo-2-yl)-2,5-diphenyl tetrazolium bromide) and cell
viability was expressed as percentages of untreated control cells. Data are
expressed as mean7s.e.m. of three independent experiments. (B) Cell
cycle arrest at G1/S checkpoint with accumulation of cells at G0/G1, little
induction of apoptosis only at high concentrations of VA (5mM) for 48h.
(C) Mild but statistically significant induction of apoptosis of cultured
thoracic cancer cells was only observed following exposure to high
concentration of VA (5.0mM;#o rþPo0.05–0.01 vs control cells or VA
(1mM)-treated cells, respectively, by ANOVA and pairwise comparison by
Bonferroni test). Cells were continuously treated with VA at either 1.0 or
5.0mM for 48h and harvested for quantitation of apoptosis by the TUNEL-
based ApoBrdU assay and flow cytometry. Data are expressed as
mean7s.e.m. of three independent experiments.
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sdepletion of pAkt in H513, H460 and TE12 cells. The VA-induced
accumulation of hyperacetylated histone H4 in H460, H513 and
TE12 cells was not altered by UCN-01 (data not shown), implying
that the synergistic interaction between STP or UCN-01 and VA to
mediate suppression of NF-kB transcriptional activity and
induction of apoptosis was independent of the HDAC-inhibitory
activity of VA (Figure 6).
Suppression of VA-mediated NF-kB activation by the PKC
inhibitor CC or by the kinase inhibitors STP and UCN-01 was
correlated with significant synergistic induction of apoptosis in
NSCLC cells H460, EsC cells TE12 or MPM cells H211 at both the
clinically relevant VA concentration of 1.0mM and particularly at
higher VA concentration of 5.0mM (Figure 7A). We further
investigated the ability of UCN-01 to mediate synergistic cytotoxic
effect in combination with VA in H322, H460, TE2 and H513
(Figure 7B). Whereas o25% of cultured thoracic cancer cells
treated with either VA (1.0 or 5.0mM) or UCN-01 (500nM)
underwent apoptosis, 60–85% of these cells were TUNEL-positive
48h after the onset of exposure to combinations of VAþUCN-01.
The magnitude of the interaction between UCN-01 (at 500nM) and
VA (1.0 or 5.0mM) to mediate additive (H460 and H513) or supra-
additive (H322, TE2, TE12, H211) apoptotic cell death varied
between cell lines at VA at 1.0mM but uniformly profound at
higher concentration of VA of 5.0mM in all cell lines (Figure 7B).
At the indicated concentrations, STP (200nM) was a more rapid
and potent inhibitor of PKC than UCN-01 (500nM) (Figure 2). As
PKC was previously demonstrated to be a positive regulator of
HDACI-mediated NF-kB activation (Maxhimer et al, 2005), it was
not surprising to observe that STP was significantly more potent
than UCN-01 in abrogating VA-mediated activation of NF-kB
(Figure 4). This was positively correlated with the more
pronounced induction of apoptosis by the STPþVA (1.0mM)
combination (Figure 8). We next investigated the effect of direct
inhibition of NF-kB by using the pharmacologic inhibitor
Parthenolide that interferes with NF-kB activation by targeting
the IkB kinase complex via inhibition of NIK- and MEKK1-
induced activation of IKKa and IKKb (Murphy et al, 1988; Bork
et al, 1997; Hehner et al, 1999; Curry et al, 2004). Parthenolide at
30mM completely abrogated VA-induced NF-kB transcriptional
activation in the representative cultured thoracic cancer cells
(Figure 4). This was associated with substantial increase of
apoptosis of cells treated with VAþParthenolide, particularly at
the low, clinically relevant concentration of VA of 1.0mM (Figures
7A and 9). These findings were in complete agreement with
observations previously reported by our group (Maxhimer et al,
2005) as well as by others (Mayo et al, 2003, Rundall et al, 2004)
and confirmed the notion that activation of NF-kB in HDACI-
treated cells impeded the ability of HDACI to effectively mediate
cell death.
DISCUSSION
In this study, we attempted to evaluate the possibility of enhancing
the cytotoxic effect of VA, a commonly used antiepileptic drug
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Figure 4 Suppression of VA-mediated activation of NF-kBb y
Calphostin C (CC), Staurosporine (STP), UCN-01 or Parthenolide in
H460, TE12 and H211 cells. Cells were transiently transfected with NF-kB-
luciferase reporter plasmid and concurrently treated with VA (1 or 5mM)i n
combination with CC (2mM), STP (200nM), UCN-01 (500nM)o r
Parthenolide (20mM). Cells were harvested 24h after the onset of drug
treatment and assayed for luciferase activity. Data are presented as fold
increase of luciferase activity, normalised for cellular proteins, from baseline
activity of untreated controls (means7s.e.m. of three independent
experiments;
þPo0.05–0.01 and
#Po0.001 vs controls by ANOVA
and pairwise comparison by Bonferroni test).
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-Actin
Figure 5 Reduction of Bcl2, BclXL, cIAP1 levels without alteration of the
expression of Bak or Bax in TE12 or H460 cells treated with VA (1.0 or
5.0mM) and UCN-01 (500nM) concurrent combinations. Representative
data of two independent experiments with similar results are shown here.
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Figure 6 Suppression of pERK1/2, pAkt and p-adducin levels in VA (1.0
or 5.0mM)-treated H460, TE12 and H513 cells by UCN-01 (500nM).
Representative data of two independent experiments with similar results
are shown here.
Anticancer effect of valproic acid
W-S Yeow et al
1441
British Journal of Cancer (2006) 94(10), 1436–1445 & 2006 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
swith HDAC-inhibitory activity, on cultured thoracic cancer cells by
combining it with the kinase inhibitor STP or its clinically relevant
analogue UCN-01. Valproic acid, by itself, is not a very efficient
anticancer agent, at least for thoracic cancers. It exerts a mild
growth-inhibitory effect in cultured thoracic cancer cells with the
in vitro IC50’s ranging from 4.0 to 8.0mM. This is mainly
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Figure 7 (A) Profound enhancement of apoptosis by the combinations of VA (1.0 or 5.0mM) with CC, STP, UCN-01 or Parthenolide in the
representative cultured thoracic cancer cells TE12 or H211. Apoptosis was quantified by TUNEL-based ApoBrdU assay and flow cytometry. (B) Summary
of the VA dose-dependent additive or supra-additive induction of apoptosis in the panel of six cultured thoracic cancer cells treated with VA and UCN-01
(500nM) combinations. Additive enhancement of apoptosis was observed in H460 and H513 cells treated with VA (1.0mMþUCN-01; *P40.05
combination effects vs sum of individual drug effects) and supra-additive enhancement of apoptosis was observed in other cell lines and combinations,
especially at the clinically relevant concentration of VA of 1.0mM (# Po0.05–0.001 combination effects vs sum of individual drug effects). The magnitude of
apoptosis induced by VAþUCN-01 was clearly dependent on VA concentrations (
þPo0.05–0.001 VA(1.0)þUCN-01 vs VA(5mM)þUCN-01). Data
are expressed as mean7s.e.m. of three independent experiments.
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sattributable to cell cycle arrest at the G1/S checkpoint and very
weak induction of apoptosis. Similar to other well-established
HDACIs like TSA or SAHA, VA significantly stimulated the NF-kB
transcriptional activity in cultured thoracic cancer cells. The
kinetics of VA-induced NF-kB activation was somewhat delayed
with discernible increase of the transcriptional activity being
observed only 18–24h of drug exposure as compared to the rapid
NF-kB activation (6–12h after the onset of drug exposure)
following TSA treatment (data not shown). Partial to complete
inhibition of VA-induced activation of NF-kB was achieved by
concurrent exposure of VA-treated cells to UCN-01, CC or STP. As
HDACI-mediated activation of NF-kB transcriptional activity is
positively regulated by PKC, it is conceivable that UCN-01 or STP,
being potent PKC inhibitor (Figures 1A and 2), suppressed NF-kB
activation in VA-treated cells via this mechanism. As a matter of
fact, high levels of p-adducin in VA-treated cells were totally
abrogated by either STP or UCN-01 (Figure 2). Suppression of
NF-kB activation by these kinase inhibitors was paralleled by the
supra-additive induction of apoptosis in combination-treated cells,
the magnitude of which appeared to correlate with the degrees of
suppressed NF-kB transcriptional activity (for instance, STP vs
UCN-01). Staurosporine (200nM) was more efficient than UCN-01
(500nM) in mediating profound apoptosis of cells concurrently
treated with the clinically relevant concentration of VA of 1.0mM
(Figure 8). Inhibition of NF-kB transcriptional activity in VA-
treated cells by STP or UCN-01 has functional significance and
directly contributed to the synergistic enhancement of apoptosis
and not merely a secondary event or a surrogate marker of
downregulation of PKC activity. In concordance with previous
reports (Rundall et al, 2004), including our own (Maxhimer et al,
2005), direct inhibition of NF-kB by using Parthenolide profoundly
potentiated apoptosis of VA-treated cells. Parthenolide, a sesqui-
terpene lactone that was first isolated from the feverfew herb
(Tanacetum parthenium) is a relatively specific small molecule
inhibitor of NF-kB (Bork et al, 1997; Hehner et al, 1999).
Parthenolide has undergone a phase I clinical trial as an anticancer
agent (Curry et al, 2004). Thus, combining clinically applicable
HDACIs such as Depsipetide, MS-275 or SAHA with NF-kB
inhibitor like Parthenolide to enhance the anticancer effect of
HDACIs may have clinically translatable potential. Targeting the
NF-kB signalling pathway, similar to targeting PKC, using
pharmacologic inhibitors to enhance the cytotoxic effects of VA
as well as other HDACIs in cancers may have practical clinical
application. This is the current focus of our laboratory
investigation.
Staurosporine and UCN-01, in addition to being PKC inhibitors,
have also been shown to inhibit the kinase activity of PDK1,
leading to the suppression of Akt phosphorylation and activation
among other downstream targets (Sato et al, 2002). Sato et al
(2004) have also demonstrated that PDK1 may directly phosphor-
ylate and activate MEK and ERK1/2. It is therefore conceivable that
STP or UCN-01 can mediate suppression of Akt and/or ERK1/2
activation. Indeed, UCN-01 has been shown to downregulate Akt
activation (but concomitantly stimulate ERK1/2) in head and
neck squamous cell carcinoma (Amornphimoltham et al, 2004;
Kondapaka et al, 2004). Continuous exposure of thoracic cancer
cells to UCN-01 (250–1000nM) in 10% FCS RPMI culture medium
(in contrast to low serum conditions as were previously described
(Amornphimoltham et al, 2004; Kondapaka et al, 2004)) led to a
profound but short-lived reduction of pAkt at 1h after drug
exposure followed by a strong activation of Akt at 24h time point.
On the other hand, there was a profound and durable inhibition
of ERK1/2 activation in UCN-01-treated cells. This is in direct
contrast to previous studies that described activation of MEK/
ERK1/2 by UCN-01 in head/neck squamous cell carcinoma cell
lines (Amornphimoltham et al, 2004; Kondapaka et al, 2004) or
leukaemia cell lines (Dai et al, 2001, 2002). The mechanism of this
discrepancy is not clear and may relate to the intrinsic difference
of cell lines and experimental conditions employed. Staurosporine
profoundly inhibited ERK1/2 activation and at the same time
mediated phosphorylation of Akt in cultured thoracic cancer cells
within the similar time interval. This effect of STP on Akt
phosphorylation was surprising, given the fact that its closely
related analogue UCN-01 suppressed Akt phosphorylation (Sato
et al, 2002; Amornphimoltham et al, 2004; Kondapaka et al, 2004;
and also our own observation). This was totally unexpected but
very reproducible in many independent experiments with our cell
lines and the molecular basis of this discrepancy was unclear. Not
surprising, however, STP or UCN-01 exerted a potent inhibitory
effect on PKC activity indicated by a profound time- and dose-
dependent depletion of p-adducin levels in treated H460 or TE12
cells. Grant and co-workers have observed reduction of MEK/
ERK1/2 activity in cells treated with combinations of HDACIs and
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Figure 8 Staurosporine (200nM) is more potent than UCN-01 (500nM)
in mediating supra-additive enhancement of apoptosis in combination with
low concentration of VA of 1.0mM (
#P¼0.0022–0.0001 VAþSTP vs
VAþUCN-01). Data are expressed as mean7s.e.m. of three independent
experiments.
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Figure 9 Supra-additive induction of apoptosis following concurrent
exposure of cultured thoracic cancer cells to the combinations of VA (1.0
or 5.0mM) and Parthenolide (30mM)(
þPo0.05–0.01 combination effects
of VA(1.0mM)þParthenolide vs the sum of individual drug effects and
#Po0.0001 combination effects of VA(5.0mM)þParthenolide vs the sum
of individual drug effects). Data are expressed as mean7s.e.m. of three
independent experiments.
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sother kinase inhibitors, including perifosine, 17-AAG or LY294002
that mediated substantial apoptosis (Dai et al, 2001; Rahmani et al,
2003b, 2005). Downregulation of MEK/ERK1/2 plays an important
role in the synergistic induction of apoptosis as forced expression
of constitutively active MEK abrogates the cytotoxic effects of these
drug combinations (Dai et al, 2001; Rahmani et al, 2003b, 2005). It
was further indicated that LY294002 enhances HDACI cytotoxicity
via downregulation of MEK/ERK1/2 activity but not via abrogation
of Akt activation (Rahmani et al, 2003b). It, therefore, appears
from the literature that abrogation of MEK/ERK1/2 signalling may
have more dominant impact on the enhancement of HDACI
cytotoxicity in cancer cells than inhibition of Akt-mediated
signalling pathway. UCN-01 and STP consistently suppressed
MEK/ERK1/2 and PKC activity in VA-treated cells and correlated
well with its synergistic interaction with VA to induce massive
apoptosis. It is not known if UCN-01- or STP-mediated inhibition
of VA-induced NF-kB activation, while conceivably attributable to
their PKC-inhibitory effect, can be mechanistically linked to their
ability to downregulate ERK1/2 or Akt activity. Inhibition of MEK/
ERK1/2 and PKC by STP or UCN-01 can both contribute to their
VA sensitisation effect in thoracic cancer cells, yet the relative
contribution of each to this effect is not clear at present. Even
though we did not focus our investigation on the effect of UCN-01
on PDK1 kinase activity, it is conceivable that via inhibition of
PDK1, which occupies an apical position in regulating multiple
downstream kinases, UCN-01 can simultaneously inhibit multiple
parallel targets including PKC, MEK/ERK1/2 and Akt.
In summary, UCN-01 and VA, at clinically achievable drug
concentrations and conditions (for instance 1.0mM of VA and
500nM of UCN-01) (Brodie and Dichter, 1996; Sausville et al,
2001), interact to mediate additive and supra-additive induction of
apoptosis of cultured thoracic cancer cells. This chemosensitisa-
tion effect of UCN-0-1 in VA-treated cells is most likely secondary
to its effect on downregulation of essential signal transduction
pathways (PKC, ERK1/2, NF-kB) that regulate HDACI-induced
apoptosis. Moreover, our study further confirms NF-kBa sa
valuable target in the ongoing development of clinically applicable
strategies to potentiate the anticancer effect of HDACIs. Within
this context, direct targeting of NF-kB using clinically relevant
pharmacologic inhibitor like Parthenolide appears to be more
effective in enhancing the anticancer property of VA, particularly
at concentration such as 1.0mM that can be readily achievable in
the clinic.
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